ORTX Key Statistics, Chart & Performance
The current stock price of ORTX is 16.7 USD. In the past month the price increased by 1.58%. In the past year, price increased by 195%.
ORTX Latest News, Press Relases and Analysis
ORTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.6 | 394.11B | ||
| AMGN | AMGEN INC | 14.35 | 169.00B | ||
| GILD | GILEAD SCIENCES INC | 14.57 | 148.09B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.17 | 110.88B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.39 | 72.79B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 814.14 | 54.85B | ||
| INSM | INSMED INC | N/A | 41.41B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.5 | 25.80B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.05 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B | ||
| INCY | INCYTE CORP | 14.82 | 18.68B |
Related stock screener links
About ORTX
Company Profile
Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The firm is engaged in transforming the lives of people affected by rare diseases through the development of curative gene therapies. Its ex vivo autologous hematopoietic stem cell (HSC), gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. Its ex vivo autologous HSC gene therapy approach seeks to transform a patient’s autologous HSCs into a gene-modified cellular drug product to treat the patient’s disease. Its lead program is OTL-200 operates under the brand name Libmeldy for eligible patients with early-onset metachromatic leukodystrophy (MLD). Its programs in immunological disorders consist of two pre-clinical programs, OTL-104 for Crohn’s disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2 (NOD2-CD), and OTL-105 for hereditary angioedema (HAE).
Company Info
ORCHARD THERAPEUTICS PLC-ADR
245 Hammersmith Road, 3Rd Floor
London EC4N 6EU GB
CEO: Bobby Gaspar
Employees: 166
Phone: 114402033846700
ORCHARD THERAPEUTICS PLC-ADR / ORTX FAQ
Can you describe the business of ORCHARD THERAPEUTICS PLC-ADR?
Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The firm is engaged in transforming the lives of people affected by rare diseases through the development of curative gene therapies. Its ex vivo autologous hematopoietic stem cell (HSC), gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. Its ex vivo autologous HSC gene therapy approach seeks to transform a patient’s autologous HSCs into a gene-modified cellular drug product to treat the patient’s disease. Its lead program is OTL-200 operates under the brand name Libmeldy for eligible patients with early-onset metachromatic leukodystrophy (MLD). Its programs in immunological disorders consist of two pre-clinical programs, OTL-104 for Crohn’s disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2 (NOD2-CD), and OTL-105 for hereditary angioedema (HAE).
Can you provide the latest stock price for ORCHARD THERAPEUTICS PLC-ADR?
The current stock price of ORTX is 16.7 USD. The price increased by 0.3% in the last trading session.
Does ORTX stock pay dividends?
ORTX does not pay a dividend.
How is the ChartMill rating for ORCHARD THERAPEUTICS PLC-ADR?
ORTX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Would investing in ORCHARD THERAPEUTICS PLC-ADR be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ORTX.
What is the expected growth for ORTX stock?
The Revenue of ORCHARD THERAPEUTICS PLC-ADR (ORTX) is expected to grow by 24% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
ORTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ORTX. When comparing the yearly performance of all stocks, ORTX is one of the better performing stocks in the market, outperforming 98.06% of all stocks.
ORTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ORTX. ORTX has a bad profitability rating. Also its financial health evaluation is rather negative.
ORTX Financial Highlights
Over the last trailing twelve months ORTX reported a non-GAAP Earnings per Share(EPS) of -4. The EPS increased by 71.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.05% | ||
| ROE | -90.81% | ||
| Debt/Equity | 0.2 |
ORTX Forecast & Estimates
7 analysts have analysed ORTX and the average price target is 16.32 USD. This implies a price decrease of -2.28% is expected in the next year compared to the current price of 16.7.
For the next year, analysts expect an EPS growth of 74.37% and a revenue growth 24% for ORTX